









Markets
/
Stocks
/
nasdaq-sght
/

Sight Sciences Inc

SGHT

5.820USD

+0.820+16.40%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

305.40MMarket Cap

LossP/E TTM



Sight Sciences Inc

5.820

+0.820+16.40%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Sight Sciences Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sight Sciences Inc's Score

Industry at a Glance

Industry Ranking

81 / 210

Overall Ranking

189 / 4615

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

4.667

Target Price

-7.22%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Sight Sciences Inc Highlights

StrengthsRisks

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma and the SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids in adult patients with evaporative dry eye disease due to meibomian gland disfunction.

Growing

The company is in a growing phase, with the latest annual income totaling USD 79.87M.

Fairly Valued

The company’s latest PE is -5.22, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 26.71M shares, decreasing 27.59% quarter-over-quarter.

Held by Joel Greenblatt

Star Investor Joel Greenblatt holds 156.47K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 7.53, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 19.56M, representing a year-over-year decrease of 8.45%, while its net profit experienced a year-over-year decrease of 3.15%.

Score

Industry at a Glance

Previous score

7.53

Change



Financials

8.99

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.18

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.62

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.72

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.15

Key Metrics

Free cash flow

No Data

Sight Sciences Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 6.87, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -5.22, which is -80.59% below the recent high of -1.01 and -50.05% above the recent low of -7.83.

Score

Industry at a Glance

Previous score

6.87

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 81/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 7.14, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Sight Sciences Inc is 4.00, with a high of 7.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.14

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

5.417

Target Price

+8.33%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

110

Total

Median

Average

Company name

Ratings

Analysts

Sight Sciences Inc

SGHT

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 8.77, which is higher than the Healthcare Equipment & Supplies industry's average of 6.74. Sideways: Currently, the stock price is trading between the resistance level at 5.82 and the support level at 3.69, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.80

Change

-0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.026

Neutral

RSI(14)

65.654

Neutral

STOCH(KDJ)(9,3,3)

37.040

Sell

ATR(14)

0.299

Low Volatility

CCI(14)

-48.840

Neutral

Williams %R

38.495

Buy

TRIX(12,20)

1.646

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

5.034

Buy

MA10

5.091

Buy

MA20

4.630

Buy

MA50

3.987

Buy

MA100

3.924

Buy

MA200

3.446

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 5.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.40. The latest institutional shareholding proportion is 51.00%, representing a quarter-over-quarter decrease of 29.27%. The largest institutional shareholder is The Vanguard, holding a total of 1.80M shares, representing 3.45% of shares outstanding, with 7.40% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Badawi (Paul)

5.27M

-0.45%

Allegro Investment, Inc.

5.09M

+26.47%

KCK, Ltd.

4.37M

Long Focus Capital Management LLC

3.15M

+0.80%

BlackRock Institutional Trust Company, N.A.

2.33M

+9.99%

Encrantz (Staffan)

1.99M

+9.78%

The Vanguard Group, Inc.

Star Investors

1.80M

+6.30%

Badawi (David)

1.68M

+2.09%

Americana Partners, LLC

863.92K

B Group, Inc.

930.00K

+11.56%

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 3.14, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 2.45. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.